Impact of Medication Withdrawal Method on Flare-Free Survival in Patients with Juvenile Idiopathic Arthritis on Combination Therapy

FRI0089 Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrextate: the prize study

(2014) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study

(2013) Yoshiya Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Contrast-enhanced MRI compared with the physical examination in the evaluation of disease activity in juvenile idiopathic arthritis

(2013) Robert Hemke et al.   EUROPEAN RADIOLOGY

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

(2013) Josef S Smolen et al.   LANCET

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

(2012) Jacqueline Detert et al.   ANNALS OF THE RHEUMATIC DISEASES

Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study

(2012) Aatke van der Maas et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

(2012) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept

(2012) N. SOLARI et al.   JOURNAL OF RHEUMATOLOGY

Clinical remission in juvenile idiopathic arthritis after termination of etanercept

(2012) Jacek Postępski et al.   RHEUMATOLOGY INTERNATIONAL

Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: A twelve-year experience

(2011) Kevin Baszis et al.   ARTHRITIS AND RHEUMATISM

Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis

(2011) Marieke H. Otten et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis

(2011) Carol A. Wallace et al.   ARTHRITIS CARE & RESEARCH

Defining Juvenile Idiopathic Arthritis Remission and Optimum Time for Disease-Modifying Anti-Rheumatic Drug Withdrawal

(2011) Thomas Broughton et al.   PEDIATRIC DRUGS

Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study

(2010) N. B. Klarenbeek et al.   ANNALS OF THE RHEUMATIC DISEASES

Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

(2010) B. Saleem et al.   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate Withdrawal at 6 vs 12 Months in Juvenile Idiopathic Arthritis in RemissionA Randomized Clinical Trial

(2010) Dirk Foell   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Discontinuation of Etanercept After Successful Treatment in Patients with Juvenile Idiopathic Arthritis

(2010) A. REMESAL et al.   JOURNAL OF RHEUMATOLOGY

The safety profile of biologic therapies for juvenile idiopathic arthritis

(2010) Philip J. Hashkes et al.   Nature Reviews Rheumatology

Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis

(2010) V. Papsdorf et al.   RHEUMATOLOGY

Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis

(2009) R. O'Mahony et al.   ANNALS OF THE RHEUMATIC DISEASES

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis

(2009) F H M Prince et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis

(2009) Olivier Brocq et al.   JOINT BONE SPINE

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

(2008) G Horneff et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

(2008) Daniel J. Lovell et al.   NEW ENGLAND JOURNAL OF MEDICINE